These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23937426)

  • 41. Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook.
    Al Mahri S; Malik SS; Al Ibrahim M; Haji E; Dairi G; Mohammad S
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
    Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
    Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibiotic effects on gut microbiota and metabolism are host dependent.
    Fujisaka S; Ussar S; Clish C; Devkota S; Dreyfuss JM; Sakaguchi M; Soto M; Konishi M; Softic S; Altindis E; Li N; Gerber G; Bry L; Kahn CR
    J Clin Invest; 2016 Dec; 126(12):4430-4443. PubMed ID: 27775551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes.
    Legrand-Poels S; Esser N; L'homme L; Scheen A; Paquot N; Piette J
    Biochem Pharmacol; 2014 Nov; 92(1):131-41. PubMed ID: 25175736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Energy and metabolic sensing G protein-coupled receptors during lactation-induced changes in energy balance.
    Friedrichs P; Saremi B; Winand S; Rehage J; Dänicke S; Sauerwein H; Mielenz M
    Domest Anim Endocrinol; 2014 Jul; 48():33-41. PubMed ID: 24906926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKβ pathways.
    Jiao P; Ma J; Feng B; Zhang H; Diehl JA; Chin YE; Yan W; Xu H
    Obesity (Silver Spring); 2011 Mar; 19(3):483-91. PubMed ID: 20829802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Free fatty acid receptors as therapeutic targets for metabolic disorders].
    Hirasawa A; Takeuchi M; Shirai R; Chen Z; Ishii S; Iida K
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):296-301. PubMed ID: 26657119
    [No Abstract]   [Full Text] [Related]  

  • 48. Dietary Fatty Acids and Their Potential for Controlling Metabolic Diseases Through Activation of FFA4/GPR120.
    Ulven T; Christiansen E
    Annu Rev Nutr; 2015; 35():239-63. PubMed ID: 26185978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diet-induced obesity and GPR120].
    Ichimura A
    Nihon Rinsho; 2013 Feb; 71(2):350-4. PubMed ID: 23631220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance.
    Pal D; Dasgupta S; Kundu R; Maitra S; Das G; Mukhopadhyay S; Ray S; Majumdar SS; Bhattacharya S
    Nat Med; 2012 Aug; 18(8):1279-85. PubMed ID: 22842477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia.
    Bernard J
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1078-83. PubMed ID: 18821469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlling inflammation: a fat chance?
    Flower RJ; Perretti M
    J Exp Med; 2005 Mar; 201(5):671-4. PubMed ID: 15753201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.
    Smith NJ; Stoddart LA; Devine NM; Jenkins L; Milligan G
    J Biol Chem; 2009 Jun; 284(26):17527-39. PubMed ID: 19398560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes.
    Patti AM; Giglio RV; Papanas N; Serban D; Stoian AP; Pafili K; Al Rasadi K; Rajagopalan K; Rizvi AA; Ciaccio M; Rizzo M
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
    Watterson KR; Hudson BD; Ulven T; Milligan G
    Front Endocrinol (Lausanne); 2014; 5():137. PubMed ID: 25221541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic role and ligands of medium- to long-chain Fatty Acid receptors.
    Hara T; Ichimura A; Hirasawa A
    Front Endocrinol (Lausanne); 2014; 5():83. PubMed ID: 24917851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. G protein-coupled receptors for energy metabolites as new therapeutic targets.
    Blad CC; Tang C; Offermanns S
    Nat Rev Drug Discov; 2012 Aug; 11(8):603-19. PubMed ID: 22790105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Free Fatty Acid Receptors and Cancer: From Nutrition to Pharmacology.
    Hopkins MM; Meier KE
    Handb Exp Pharmacol; 2017; 236():233-251. PubMed ID: 27757756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms.
    Lin HV; Frassetto A; Kowalik EJ; Nawrocki AR; Lu MM; Kosinski JR; Hubert JA; Szeto D; Yao X; Forrest G; Marsh DJ
    PLoS One; 2012; 7(4):e35240. PubMed ID: 22506074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Free fatty acid receptors in the endocrine regulation of glucose metabolism: Insight from gastrointestinal-pancreatic-adipose interactions.
    Zhao YF
    Front Endocrinol (Lausanne); 2022; 13():956277. PubMed ID: 36246919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.